Abstract
A selective, rapid, accurate and precise stability-indicating RP-HPLC method was developed for monitoring vilazodone in the presence of its degradation products (DPs) in API and pharmaceutical dosages. Chromatographic separation was achieved using a Grace phenyl C18 column (250 × 4.6 mm, 5 µm particle size) at a flow rate of 1.0 mL min−1 with a linear gradient elution of ammonium acetate buffer (10 mM, pH 5.0 adjusted by acetic acid) with acetonitrile as the mobile phase. Detection was performed at 240 nm. The chromatographic conditions were optimized by the design of experiments to obtain the best possible separation with a minimum number of trials. A face-centered central composite design (three levels for each factor) was employed for optimization, and an interaction of the independent variables (pH of mobile phase, column temperature and % of organic modifier) on the resolution of critical pairs was studied. The drug was subjected to the stress conditions of hydrolytic (acid, base and neutral), oxidative, thermal and photolytic degradation. It was found to be degraded significantly in hydrolytic (basic and acid) and oxidative conditions, while it was stable in neutral hydrolytic, thermal and photolytic conditions. LC-QTOF/MS/MS studies were carried out to characterize the major DPs. The method was fully validated for selectivity, linearity, accuracy, precision and robustness in compliance with ICH guideline Q2 (R1).
Similar content being viewed by others
References
Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005) Arch Gen Psychiatry 62:1097
Kessler RC, Berglund P, Demler O (2003) JAMA 289:3095–3105
Jones J (2012) PharmaNote 27
FDA (1987) Guideline for submitting documentation for the stability of human drugs and biologics. Food and Drug Administration, Rockville
International Conference on Harmonization (ICH) Guideline of Technical Requirements for Registration of Pharmaceuticals for Human Use (2000) Q1A (R2) stability testing of new drug substances and products. International Conference on Harmonisation, IFPMA, Geneva
Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040
US Food and Drug Administration (FDA) (2007) Department of Health and Human Services, pharmaceutical quality for the 21st century a risk-based approach progress report. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm128080.html
International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009) Topic Q8 (R2): pharmaceutical development. ICH, Geneva
International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) Topic Q9: quality risk management. ICH, Geneva
International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2008) Topic Q10: pharmaceutical quality system. ICH, Geneva
Karmarkar S, Garber R, Genchanok Y, George S, Yang X, Hammond R (2011) J Chromatogr Sci 49:439–446
Schmidt AH, Molnar I (2013) J Pharm Biomed Anal 78–79:65–74
Garg LK, Reddy VS, Sait SS, Krishnamurthy T, Vali SJ, Reddy AM (2013) Chromatographia 76:1697–1706
Smajic M, Vujic Z, Mulavdic N, Brboric J (2013) Chromatographia 76:419–425
Srinubabu G, Jaganbabu K, Sudharani B, Venugopal K, Girizasankar G, Rao J (2006) Chromatographia 64:95–100
Harang V, Karlsson A, Josefson M (2001) Chromatographia 54:703–709
Dincel A, Basci NE (2007) Chromatographia 66:81–85
Snyder LR, Kirkland JJ, Dolan JW (1997) Practical HPLC method development. Wiley, New Jersey, p 240
Snyder LR, Kirkland JJ, Glajch JL (1997) Practical HPLC method development. Wiley, New York, pp 411–415
Beg QK, Sahai V, Gupta R (2003) Process Biochem 39:203–209
Kalariya PD, Namdev D, Srinivas R, Gananadhamu S (2014) J Saudi Chem Soc. doi:10.1016/j.jscs.2014.1004.1004
Kalariya PD, Raju B, Borkar RM, Namdev D, Gananadhamu S, Nandekar PP, Sangamwar AT, Srinivas R (2014) J Mass Spectrom 49:380–391
Namdev D, Borkar RM, Raju B, Kalariya PD, Rahangdale VT, Gananadhamu S, Srinivas R (2014) J Pharm Biomed Anal 88:245–255
Talluri MVN, Kandimalla NR, Bandu R, Chundi D, Marupaka R, Ragampeta S (2013) J Pharm Anal 4:107–116
Mohan A, Shanmugavel S, Goyal A, Venkataraman BR, Saravanan D (2009) Chromatographia 69:1211–1220
Zhang Y, Wang Z, Ma Z, Cheng Y (2008) Chromatographia 68:903–909
Qi M, Wang P, Xiao G (2004) Chromatographia 59:373–379
Dyakonov T, Muir A, Nasri H, Toops D, Fatmi A (2010) Pharm Res 27:1318–1324
Saeed MS, Ibrahim MN, Ahmed MEE (2012) Der Chemica Sinica 3:292–298
Sridhar L, Karthikraj R, Murty M, Raju NP, Vairamani M, Prabhakar S (2013) Int J Mass Spectrom 333:15–20
Bremner JB, Browne EJ, Davies PE, Thuc LV (1980) Aust J Chem 33:833–841
ICH Q2 (R1) International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) Topic Q2 (R1): validation of analytical procedures: text and methodology
Acknowledgments
The authors wish to thank Dr. Ahmed Kamal, project director, NIPER, Hyderabad, India, and Dr. M. Lakshmi Kantam, Director, IICT, Hyderabad, for facilities and their cooperation. P.K. is thankful to the Ministry of Pharmaceuticals, New Delhi, for the award of a Junior Research Fellowship.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kalariya, P.D., Talluri, M.V.N.K. & Ragampeta, S. Experimental Design Approach for Selective Separation of Vilazodone HCl and Its Degradants by LC-PDA and Characterization of Major Degradants by LC/QTOF–MS/MS. Chromatographia 77, 1299–1313 (2014). https://doi.org/10.1007/s10337-014-2739-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-014-2739-0